Cholesterol Newswire

Comprehensive Real-Time News Feed for Cholesterol.

Results 1 - 20 of 897 in Cholesterol

  1. AbbVie Sales Blow Past ExpectationsRead the original story w/Photo

    10 min ago | Fox News

    ... Synthroid, whose sales rose 24 percent to $200 million. But many others suffered sales declines, including its cholesterol treatments and its AndroGel testosterone gel, whose sales have been hurt by growing concerns that such medicines may increase ...

    Comment?

  2. AbbVie sales blow past forecasts, fueled by HumiraRead the original story w/Photo

    47 min ago | Reuters

    ... Synthroid, whose sales rose 24 percent to $200 million. But many others suffered sales declines, including its cholesterol treatments and its AndroGel testosterone gel, whose sales have been hurt by growing concerns that such medicines may increase ...

    Comment?

  3. UPDATE 1-AbbVie sales blow past forecasts, fueled by HumiraRead the original story

    2 hrs ago | Reuters

    ... Synthroid, whose sales rose 24 percent to $200 million. But many others suffered sales declines, including its cholesterol treatments and its AndroGel testosterone gel, whose sales have been hurt by growing concerns that such medicines may increase ...

    Comment?

  4. A Little KajuspeakRead the original story w/Photo

    Sep 15, 2013 | Outlook

    ... 'good fats', I am full of Oelic acid, mono unsaturated fat (mufa), which helps you lower triglyceride and bad cholesterol. Now, don't I qualify as a heart protector? I am told no one's gonna eat me just because I am yummy to taste, crunchy and ...

    Comment?

  5. Health-care spending projected to grow at slowest pace in 17 yearsRead the original story w/Photo

    16 hrs ago | The Globe and Mail

    ... this year. Part of the explanation is that patents for several blockbuster drugs - including widely used anti-cholesterol pills like Lipitor and Crestor - have expired, meaning provincial governments can turn to cheaper generic versions instead. The ...

    Comment?

  6. Plop, Plop, Fizz, Fizz - Oh What a Relief it IsRead the original story w/Photo

    Friday Oct 24 | Natural Holistic Health

    ... use low-fat methods when cooking. Make your morning meal oatmeal. It's high in fiber, low in saturated fat and cholesterol and when combined with skim milk, gives you a calcium-charged boost to your day. By adding blueberries or raisins you'll be ...

    Comment?

  7. Monica Lewis: Prescription drug names are weird, complicatedRead the original story w/Photo

    Wednesday | Erie Times News

    ... Take Zocor, for example. This is one of the top 10 most commonly prescribed drugs. It is designed for lowering cholesterol, yet it sounds like the name of the fortune teller with the crystal ball at the county fair. Or the rheumatoid arthritis drug, ...

    Comment?

  8. gemfibrozil, LopidRead the original story w/Photo

    Wednesday | MedicineNet

    ... at UCLA/Cedars-Sinai Medical Center in Los Angeles. DRUG CLASS AND MECHANISM: Gemfibrozil is a blood lipid and cholesterol-altering medicine. It is classified as a fibric acid derivative similar to fenofibrate (Tricor). It reduces triglycerides and ...

    Comment?

  9. NIH Study Explores Heart Disease Prevention in HIV PatientsRead the original story

    Wednesday | P&T Community

    The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs in preventing cardiovascular disease in individuals with long-term human immunodeficiency virus infections. This group, which includes patients receiving antiretroviral therapy as well as "elite controllers" who can limit the virus without ART, has a higher risk of developing heart disease and stroke compared with the general population.

    Comment?

  10. Effectiveness of combination therapy with statin and another...Read the original story

    Wednesday | CiteULike

    ... population characteristics, interventions, and outcomes (deaths, ASCVD events, low-density lipoprotein [LDL] cholesterol level, adherence, and adverse events). Two independent reviewers assessed risk of bias. A total of 36 trials were included. ...

    Comment?

  11. Pfizer's third quarter better than expectedRead the original story w/Photo

    Tuesday | The Day

    ... exclusivity on several of its biggest blockbuster drugs that had raked in billions annually. Those are led by cholesterol fighter Lipitor, which lost patent protection in November 2011 after nearly a decade as the world's top-selling drug. Pfizer ...

    Comment?

  12. NIH-led study explores prevention of heart disease in HIV-infected peopleRead the original story

    Saturday Oct 25 | National Institutes of Health

    The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy as well as "elite controllers" who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population.

    Comment?

  13. Pfizer thrives on emerging market growthRead the original story w/Photo

    Tuesday Oct 28 | Salt Lake Tribune

    ... exclusivity on several of its biggest blockbuster drugs that had raked in billions annually. Those are led by cholesterol fighter Lipitor, which lost patent protection in November 2011 after nearly a decade as the world's top-selling drug. Pfizer ...

    Comment?

  14. Study explores prevention of heart disease in HIV-infected peopleRead the original story w/Photo

    Tuesday Oct 28 | PhysOrg Weblog

    The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy as well as "elite controllers" who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population.

    Comment?

  15. Emerging Markets Boost Pfizer Q3Read the original story w/Photo

    Tuesday Oct 28 | Hispanic Business

    ... exclusivity on several of its biggest blockbuster drugs that had raked in billions annually. Those are led by cholesterol fighter Lipitor, which lost patent protection in November 2011 after nearly a decade as the world's top-selling drug. Pfizer ...

    Comment?

  16. Amgen, under investor pressure, outlines strategyRead the original story w/Photo

    Tuesday Oct 28 | MarketWatch

    ... a corner, and they've touted study results from three cancer drugs and two cardiovascular medicines, including a cholesterol-lowering drug that is expected to be a blockbuster seller. Mr. Bradway in July announced plans to cut costs by closing some ...

    Comment?

  17. UPDATE 2-Sanofi warns key diabetes business will slow in 2015Read the original story

    Tuesday Oct 28 | Reuters

    ... diversified model and had considerably replenished its pipeline of new drugs, including a potential blockbuster cholesterol treatment - a follow-on to its top-selling diabetes drug Lantus and the world's first dengue vaccine. "The confidence we have ...

    Comment?

  18. MomentumWE have OvercomeRead the original story

    Monday Oct 27 | American Reporter

    We made food history last week when Indiana declared the Wick's sugar cream as its very own State Pie. I celebrated the event by having my wife tell me I couldn't eat any because of my cholesterol.

    Comment?

  19. Dow 30 Earnings: Merck and Co. Third Quarter 2014Read the original story

    Monday Oct 27 | Value Line

    ... healthcare and specialty chemical products. Important product names include SINGULAIR (asthma); VYTORIN/ZOCOR (cholesterol-lowering agents); FOSAMAX (osteoporosis); CRIXIVAN (HIV/AIDS); VASOTEC/PRINIVIL (angiotensin converting enzyme (ACE) ...

    Comment?

  20. UPDATE 2-Sanofi chief wrote to board asking to keep his job -Les EchosRead the original story

    Monday Oct 27 | Reuters

    ... regain investors' confidence by replenishing its pipeline of new drugs, including with a potential blockbuster cholesterol treatment, a follow-on to Lantus, and the world's first dengue vaccine. ($1 = 0.7876 euro) (Reporting by Natalie Huet and ...

    Comment?